Myocarditis is inflammation of the heart muscle that can impair contractile function and electrical conduction, ranging from mild self-limited illness to fulminant heart failure. Viral infections are common triggers.
Recent studies on mRNA COVID-19 vaccines reveal spike protein and mRNA persistence beyond 3.5 years, no brain changes on MRI in healthy adults, and stress responses in heart cells in vitro.
Cardiol Therapeutics announced that Phase II MAvERIC results in recurrent pericarditis were accepted for publication in JAHA. The company also provided updates on its Phase III MAVERIC trial, published ARCHER trial results, and CRD-38 development.
A Senate subcommittee heard testimony that mRNA COVID vaccines were considered the likely cause in 73.9% of post-vaccine deaths in a large autopsy series. Separately, NEJM research identified the K31E antibody mutation and adenovirus protein pVII as triggers of rare VITT blood clots. The findings may enable safer adenoviral vaccines.
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
Invivyd reported progress in the Phase 3 DECLARATION trial of VYD2311, with top-line data now expected in Q3 2026 after a sample size increase of about 500 subjects. The company also aligned with the FDA on the LIBERTY Phase 3 study, a pediatric study plan for DRUMMER, and advanced measles antibody candidate VMS063.
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
Solid Biosciences has secured FDA alignment on a registration pathway for its Duchenne muscular dystrophy gene therapy SGT-003, with 36 patients dosed to date showing no drug-induced liver injury, myocarditis, or other serious adverse events reported with competing therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07737470 |
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research |
NOT_YET_RECRUITING | |
| NCT07617844 |
Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease |
RECRUITING | |
| NCT07482865 |
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support |
NOT_YET_RECRUITING | NA |
| NCT07354646 |
The Application of T1 Mapping in Real-World |
RECRUITING | |
| NCT07325968 |
Cardiac MRI in Myocarditis and Inflammatory Cardiomyopathy |
ENROLLING_BY_INVITATION | |
| NCT07175948 |
Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital |
NOT_YET_RECRUITING | |
| NCT07086144 |
Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis |
RECRUITING | NA |
| NCT07077304 |
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases |
RECRUITING | |
| NCT06889662 |
GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis. |
RECRUITING | |
| NCT06748261 |
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA |
NOT_YET_RECRUITING |
